Turn Therapeutics™ Closes Series B Round to Fuel Lead Atopic Dermatitis Program Trial and Pipeline Expansion

News provided by

Oct 03, 2019, 07:00 ET

LOS ANGELES, Oct. 3, 2019 /PRNewswire/ -- Turn Therapeutics™, Inc., a Los Angeles-based pharmaceutical and medical device company, has announced the closing of its fully-subscribed series B financing. The capital raised will fund a large-scale, pre-launch, phase 4 trial for AtopX™ Eczema Emulsion, with enrollment scheduled to begin in Q1, 2020. The series B financing will also support advancement of additional infectious disease and dermatology programs based on Turn's proprietary PermaFusion™ technology platform.

"AtopX™ is an extensively-studied, well-tolerated, non-steroidal, FDA cleared product indicated for the management of atopic, irritant, and radiation dermatitis. With this new capital, we will commence a large-scale, phase 4 trial specifically for the management of atopic dermatitis that will support the planned launch of AtopX™ in this high need space. We expect AtopX™ to be well-received by the commercial market due to its ease of use and substantial safety profile," says Bradley Burnam, CEO of Turn Therapeutics™.

The phase 4, adaptive trial design will assess safety and efficacy of AtopX™ in moderate to severe eczema patients as its primary endpoint, as well as employ the traditional quality of life and comfort indexes typical of such trials. In addition, the company will continue to advance its pipeline infectious disease and dermatology programs, including new drug candidates to treat shingles of the eye and onychomycosis.

The Series B round included investment from existing investors and new, high-level family office investors with expertise in the biotech space. The round closed on September 30, 2019.

About Turn Therapeutics™:
Turn Therapeutics is a concept-to-approval research and development organization focused on novel, best in class products for infection control, skin disease, and wound care. The company's proprietary technologies are used every day by world-leading healthcare institutions to care for a variety of skin and wound conditions. For more information, visit www.turntherapeutics.com.

About PermaFusion™:
PermaFusion™ is a first of its kind, petrolatum-based, liquid-in-oil suspension technology that literally fuses liquid and oil. Active ingredients are permanently suspended in liquid nanodroplets with an average size of 1.3 micron within the lipid carrier. PermaFusion™ enables maximum bioavailability of active ingredients, yet at minimal concentration, which reduces the risk of side effects. For more information, visit https://turntherapeutics.com/delivery-technology/.

Contact:
Turn Therapeutics, Inc.
818-564-4011

The statements contained herein may include prospects, statements of future expectations, and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance, or events may differ materially from those expressed or implied in such forward-looking statements.

SOURCE Turn Therapeutics